Retatrutide vs Tirzepatide vs Semaglutide: Receptor Targets and Research Status
A research-framed comparison of three GLP-class peptides by what they actually act on at the receptor level (single, dual and triple agonism) and where each one currently sits in the clinical-trial and approval pipeline. No outcome promises, no dosing, no medical advice.
The short answer: single vs dual vs triple receptor agonism
The cleanest way to tell these three peptides apart is by the receptors they target. Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual agonist, adding the GIP receptor. Retatrutide is a triple agonist, adding the glucagon receptor on top of GLP-1 and GIP. Semaglutide and tirzepatide are approved prescription medicines studied in large trials. Retatrutide is investigational and remains in late-stage (Phase 3) research.
This page is general research-and-mechanism education, not medical or legal advice. NovaPeptides supplies retatrutide for research use only. We do not supply semaglutide or tirzepatide, which are registered prescription medicines. Nothing here is a claim that any of these peptides treats, cures or prevents any condition, and no outcome should be expected from research material.
Receptor targets: the spine of the comparison
Incretin receptor agonists are peptides designed to activate the same gut-hormone receptors the body already uses to coordinate appetite and glucose handling. The difference between these three molecules is simply how many of those receptor pathways each one engages. That single, dual or triple distinction is the core axis researchers use to categorise them.
- GLP-1 receptor: activation is associated in research with appetite and satiety signalling and with glucose-dependent insulin signalling. This is the shared backbone of all three peptides.
- GIP receptor: a second incretin pathway studied alongside GLP-1. It is the receptor tirzepatide adds beyond semaglutide, making tirzepatide a dual GLP-1 plus GIP agonist.
- Glucagon receptor: the differentiator that defines retatrutide. The glucagon pathway has been investigated in research for its role in energy expenditure and hepatic (liver) metabolism. Engaging it is what makes retatrutide a triple agonist rather than a dual one.
So the progression reads as an additive stack: GLP-1 alone (semaglutide), then GLP-1 plus GIP (tirzepatide), then GLP-1 plus GIP plus glucagon (retatrutide). More receptor targets does not automatically mean a better or stronger result for any individual, and we make no such claim. It simply means a broader set of pathways is being engaged and studied.
Comparison table: receptor targets and research status
The table below sets the three peptides side by side on the two axes that matter for a research audience: which receptors each one targets, and where each currently sits in the trial and approval pipeline. All three are once-weekly injectable peptides in their primary studied formats; semaglutide also exists in an oral form.
| Peptide | Receptor targets | Class | Regulatory / research status | Examples of what it has been studied for |
|---|---|---|---|---|
| Semaglutide | GLP-1 | Single agonist | FDA-approved and TGA-registered prescription medicine. The longest-studied of the three. | Studied in trials relating to type 2 diabetes and chronic weight management; an oral semaglutide formulation has also been studied for cardiovascular risk in type 2 diabetes (the SOUL trial). |
| Tirzepatide | GLP-1 + GIP | Dual agonist | FDA-approved and TGA-registered prescription medicine. Approved more recently than semaglutide. | Studied in trials relating to type 2 diabetes and chronic weight management; the SURMOUNT-OSA programme studied moderate-to-severe obstructive sleep apnoea in adults with obesity. |
| Retatrutide | GLP-1 + GIP + glucagon | Triple agonist | Investigational. Developed by Eli Lilly. NOT FDA-approved, NOT TGA-approved and NOT on the ARTG. Currently in Phase 3 (the TRIUMPH programme). Supplied by NovaPeptides for research use only. | Being studied across the TRIUMPH Phase 3 programme in populations such as obesity, obesity with type 2 diabetes, obesity with cardiovascular disease and obesity with knee osteoarthritis, plus sleep apnoea, chronic low back pain, cardiovascular/renal outcomes and MASH (an earlier MASH signal came from a Phase 2a study published in Nature Medicine). |
Retatrutide is investigational. It is not approved for human use anywhere, including Australia, where it is not on the ARTG and not TGA-approved. Semaglutide and tirzepatide, by contrast, are approved prescription medicines. We mention their brand status only as factual context; NovaPeptides does not supply them as medicines.
Where each peptide sits in the research pipeline
Beyond the receptor count, the three peptides differ sharply in how far along the regulatory pathway they are. This is worth understanding before forming any view, because a Phase 3 investigational compound and an established approved medicine are not the same kind of thing.
- Semaglutide is the most established and longest-studied of the three, with an extensive published trial history and multiple approvals across diabetes and weight-management indications.
- Tirzepatide is approved across diabetes and weight management, and through the SURMOUNT-OSA programme was studied for obstructive sleep apnoea in adults with obesity.
- Retatrutide is the newest and least far along. Its TRIUMPH Phase 3 programme runs roughly eight pivotal trials in parallel plus a separate large cardiovascular outcomes trial.
On the retatrutide timeline specifically: the TRIUMPH Phase 3 programme is ongoing, with readouts from its pivotal trials expected to emerge over time, and a direct head-to-head retatrutide-versus-tirzepatide trial has also been reported. Exact readout dates are best confirmed against primary trial registry sources, as timelines for ongoing studies can shift. These are trial-status facts, that is, what is being studied and when readouts are expected. They are not efficacy promises, and we deliberately do not quote trial percentages here, because those figures belong to specific named studies and study designs rather than to any outcome a buyer should expect.
How NovaPeptides fits in
NovaPeptides supplies retatrutide strictly for research use only. We do not sell, supply or promote semaglutide or tirzepatide, and nothing on this page should be read as offering any of these peptides for human use. Our role is to provide research material with the documentation a research setting expects.
- Complete research kits with the components needed to work with the material
- Janoshik third-party Certificate of Analysis (COA) lab verification on the batch (our retatrutide report is Janoshik test #165694, batch-tested purity 99.80%)
- Australian shipping
- WhatsApp enquiry as the simple way to ask questions before you decide
This comparison is general research and educational information. It is not medical, legal or therapeutic advice, and it is not a protocol. We provide no dosing, titration or how-to-use guidance here. If you have questions about the regulatory situation or about any peptide, seek appropriately qualified advice. Research-use-only material is not for human consumption.
Frequently asked questions
What is the actual difference between retatrutide, tirzepatide and semaglutide?+
The defining difference is receptor targeting. Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 plus GIP agonist. Retatrutide is a triple GLP-1 plus GIP plus glucagon agonist. They also differ in research status: semaglutide and tirzepatide are approved medicines, while retatrutide is investigational and in Phase 3.
Why is retatrutide called a triple agonist?+
Because it is designed to engage three receptors rather than one or two. It shares the GLP-1 and GIP pathways with the other peptides and adds the glucagon receptor. The glucagon pathway has been investigated in research for its role in energy expenditure and hepatic metabolism. Adding it is what distinguishes retatrutide from a dual agonist such as tirzepatide.
Is retatrutide approved or legal to use in Australia?+
Retatrutide is investigational. It is not approved by the TGA for human use and is not on the ARTG. It is supplied as a research-use-only compound, not as a medicine. Semaglutide and tirzepatide are separately TGA-registered prescription medicines, but NovaPeptides does not supply those. This is general information, not legal or medical advice.
Does adding more receptor targets make retatrutide more effective?+
We do not make that claim. More receptor targets means a broader set of pathways is being engaged and studied, not a guaranteed or superior result for any individual. Retatrutide is still in Phase 3 research, and how it compares to other peptides is exactly what ongoing trials, including a reported head-to-head study against tirzepatide, are designed to investigate.
What is the TRIUMPH programme?+
TRIUMPH is retatrutide's Phase 3 clinical programme, run by Eli Lilly. It comprises roughly eight pivotal trials in parallel plus a separate large cardiovascular outcomes trial, studying populations such as obesity, obesity with type 2 diabetes, obesity with cardiovascular disease and obesity with knee osteoarthritis, among others. These are studies in progress, not approvals or outcome guarantees.
Are all three peptides taken the same way?+
In their primary studied formats all three are once-weekly injectable peptides. Semaglutide additionally has an oral form. This page does not provide any dosing, titration or administration guidance; it is research and mechanism education only.
Questions? Talk to us.
Message us on WhatsApp and we will walk you through the kits, the COAs, reconstitution and the dose tool.
Chat with us on WhatsApp